Outward-facing lysine residues on red blood cell membrane proteins (RBC surface lysines)

Outward-facing lysine residues on red blood cell (RBC) membrane proteins are primary targets for covalent bioconjugation in advanced drug delivery systems (Muzykantov, 2010). These residues are abundant on the extracellular domains of major membrane proteins, most notably Band 3 (Anion Exchanger 1) and Glycophorin A, which provide a dense array of primary amines for chemical modification (Villa et al., 2016). By utilizing amine-reactive linkers such as N-hydroxysuccinimide (NHS) esters, therapeutic payloads including enzymes, antibodies, and nanoparticles can be stably attached to the RBC surface (Brenner et al., 2018). This "RBC hitchhiking" strategy exploits the long circulatory lifespan of erythrocytes to dramatically extend the half-life of drugs that would otherwise be rapidly cleared by the kidneys or the reticuloendothelial system (Magnani et al., 2012). Beyond half-life extension, targeting these lysine residues allows for the creation of vascular carriers that can deliver drugs to specific organs, such as the lungs, through mechanical filtration of RBC-bound particles in the pulmonary capillary bed (Brenner et al., 2018). However, the modification of surface lysines must be carefully controlled, as excessive conjugation can alter the RBC's membrane flexibility and osmotic fragility, leading to premature splenic clearance or hemolysis (Villa et al., 2016). In clinical research, this target is explored for treating lysosomal storage diseases, enzyme deficiencies, and for inducing immunological tolerance to protein drugs (Magnani et al., 2012).

Other names

Erythrocyte surface aminesRBC membrane lysinesSurface-exposed lysine residuesExtracellular lysine side chains

Covalent bioconjugation to primary amines for erythrocyte hitchhiking and circulatory half-life extension